US 12,304,961 B2
PD-L1 and OX40 binding proteins for cancer regulation
Jhong-Jhe You, Taipei (TW); Ching-Hsuan Hsu, Taoyuan (TW); Po-Lin Huang, Taipei (TW); Hung-Tsai Kan, New Taipei (TW); Ting-Yi Chang, New Taipei (TW); Hsin-Ta Hsieh, Taipei (TW); and Jeng-Horng Her, San Jose, CA (US)
Assigned to AP Biosciences, Inc., Taipei (TW)
Filed by AP Biosciences, Inc., Taipei (TW)
Filed on Mar. 9, 2023, as Appl. No. 18/181,339.
Application 18/181,339 is a continuation of application No. 16/871,799, filed on May 11, 2020, granted, now 11,643,470.
Application 16/871,799 is a continuation of application No. PCT/US2018/067868, filed on Dec. 28, 2018.
Claims priority of provisional application 62/611,543, filed on Dec. 29, 2017.
Prior Publication US 2023/0322939 A1, Oct. 12, 2023
Int. Cl. A61K 39/395 (2006.01); A61P 35/00 (2006.01); C07K 16/28 (2006.01); A61K 39/00 (2006.01)
CPC C07K 16/2878 (2013.01) [A61P 35/00 (2018.01); C07K 16/2827 (2013.01); A61K 2039/505 (2013.01); C07K 2317/31 (2013.01); C07K 2317/52 (2013.01); C07K 2317/55 (2013.01); C07K 2317/622 (2013.01)] 19 Claims
OG exemplary drawing
 
15. An antibody-drug conjugate comprising:
a therapeutic agent; and
an antibody or an antigen-binding portion thereof binding PD-L1 and/or OX40, wherein the therapeutic agent is covalently conjugated to the antibody or the antigen-binding portion thereof by a linker;
wherein the antibody or the antigen-binding portion thereof is:
a) an antibody or an antigen-binding portion thereof binding to OX40, comprising:
a heavy chain variable region and a light chain variable region respectively comprising an amino acid sequence of:
amino acid 128-246 of SEQ ID NO: 10 and amino acid 1-112 of SEQ ID NO: 10;
or
b) a bispecific antibody comprising at least one polypeptide chain, wherein the polypeptide chain comprises:
an OX40 binding site, comprising:
a heavy chain variable region and a light chain variable region respectively comprising an amino acid sequence of amino acid 128-246 of SEQ ID NO: 10 and amino acid 1-112 of SEQ ID NO: 10;
and
a PD-L1 binding site, comprising:
a heavy chain variable region and a light chain variable region respectively comprising an amino acid sequence of SEQ ID NO: 2 and amino acid 1-111 of SEQ ID NO: 1.